ETNB [NASD]
89bio, Inc.
Index- P/E- EPS (ttm)-4.48 Insider Own1.00% Shs Outstand19.52M Perf Week-3.14%
Market Cap54.27M Forward P/E- EPS next Y-4.22 Insider Trans-28.31% Shs Float10.32M Perf Month0.72%
Income-90.10M PEG- EPS next Q-1.17 Inst Own95.70% Short Float7.78% Perf Quarter-38.90%
Sales- P/S- EPS this Y-45.70% Inst Trans-4.08% Short Ratio4.22 Perf Half Y-81.63%
Book/sh7.30 P/B0.38 EPS next Y-11.40% ROA- Target Price27.44 Perf Year-84.04%
Cash/sh6.46 P/C0.43 EPS next 5Y16.00% ROE- 52W Range2.00 - 22.31 Perf YTD-78.73%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-88.30% Beta-
Dividend %- Quick Ratio7.40 Sales past 5Y- Gross Margin- 52W Low30.50% ATR0.29
Employees41 Current Ratio7.40 Sales Q/Q- Oper. Margin- RSI (14)45.12 Volatility11.39% 12.00%
OptionableYes Debt/Eq0.19 EPS Q/Q- Profit Margin- Rel Volume0.77 Prev Close2.78
ShortableYes LT Debt/Eq0.14 EarningsMar 24 AMC Payout- Avg Volume190.42K Price2.61
Recom1.60 SMA203.51% SMA50-15.86% SMA200-76.57% Volume146,401 Change-6.12%
May-12-22Upgrade Raymond James Outperform → Strong Buy $33 → $12
Dec-20-21Initiated H.C. Wainwright Buy $46
Oct-26-21Resumed Cantor Fitzgerald Overweight $49
Jul-29-21Resumed BTIG Research Buy $60
May-25-21Downgrade Raymond James Strong Buy → Outperform $65 → $35
Apr-21-21Initiated Cantor Fitzgerald Overweight $58
Oct-19-20Initiated Raymond James Strong Buy $65
Sep-25-20Upgrade BofA Securities Neutral → Buy $37 → $43
Jul-31-20Initiated Piper Sandler Overweight $54
Jul-23-20Initiated BTIG Research Buy
Jul-07-20Initiated Chardan Capital Markets Buy $58
Dec-09-19Initiated SVB Leerink Outperform
Dec-09-19Initiated RBC Capital Mkts Outperform
Dec-09-19Initiated Oppenheimer Outperform
Dec-09-19Initiated BofA/Merrill Neutral
May-11-22 04:05PM  
May-03-22 08:00AM  
Apr-26-22 08:00AM  
Mar-25-22 08:35AM  
Mar-24-22 04:05PM  
Mar-01-22 04:03PM  
Feb-24-22 08:00AM  
Feb-09-22 08:00AM  
Feb-03-22 04:30AM  
Jan-25-22 07:58AM  
Jan-24-22 04:05PM  
Jan-05-22 04:54AM  
Nov-14-21 06:30PM  
Nov-11-21 04:05PM  
Nov-03-21 08:00AM  
Oct-25-21 04:05PM  
Oct-04-21 09:29AM  
Sep-21-21 08:00AM  
Sep-08-21 04:15PM  
Aug-12-21 04:05PM  
Aug-03-21 04:15PM  
Aug-02-21 08:30AM  
Jul-09-21 06:22AM  
Jun-16-21 08:00AM  
Jun-10-21 08:30AM  
May-12-21 04:05PM  
May-07-21 04:50AM  
May-05-21 08:00AM  
Apr-05-21 08:00AM  
Mar-24-21 04:05PM  
Mar-20-21 11:00AM  
Mar-11-21 08:00AM  
Mar-03-21 08:00AM  
Feb-24-21 08:00AM  
Feb-18-21 08:00AM  
Jan-22-21 08:36AM  
Jan-05-21 08:00AM  
Jan-04-21 08:00AM  
Dec-18-20 01:40AM  
Nov-24-20 08:00AM  
Nov-13-20 08:00AM  
Nov-10-20 04:02PM  
Nov-08-20 09:29AM  
Nov-02-20 08:00AM  
Sep-28-20 05:18PM  
Sep-23-20 07:00AM  
Sep-16-20 08:51PM  
Sep-14-20 05:21PM  
07:01AM  
Sep-13-20 07:53PM  
Sep-03-20 08:30AM  
Aug-13-20 04:05PM  
Aug-11-20 08:32AM  
Aug-10-20 12:15PM  
12:09PM  
Aug-03-20 04:05PM  
Jul-24-20 06:12PM  
Jul-13-20 10:18AM  
Jul-10-20 08:26AM  
Jul-07-20 09:30PM  
Jul-06-20 06:30AM  
Jun-04-20 08:00AM  
May-27-20 05:26PM  
May-13-20 04:05PM  
May-08-20 07:30AM  
Apr-13-20 08:30AM  
Mar-25-20 04:05PM  
Mar-18-20 04:05PM  
Feb-21-20 04:05PM  
Feb-11-20 06:43AM  
Dec-18-19 04:05PM  
Nov-13-19 04:02PM  
Nov-11-19 09:25AM  
08:22AM  
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Waisbourd RamSee RemarksFeb 01Option Exercise1.937,00013,5107,000Feb 03 04:30 PM
Waisbourd RamSee RemarksFeb 01Sale5.707,00039,9000Feb 03 04:30 PM
PALEKAR ROHANChief Executive OfficerJan 28Buy6.142,50015,35045,845Jan 31 04:30 PM
PALEKAR ROHANChief Executive OfficerJan 27Buy7.505,00037,50043,345Jan 31 04:30 PM
ORBIMED ADVISORS LLC10% OwnerJan 26Sale8.3821,482180,0191,829,433Jan 27 05:22 PM
ORBIMED ADVISORS LLC10% OwnerJan 25Sale8.4049,091412,3641,840,175Jan 27 05:22 PM
Waisbourd RamSee RemarksDec 16Option Exercise1.937,00013,5107,000Dec 20 04:30 PM
Waisbourd RamSee RemarksDec 16Sale11.487,00080,3600Dec 20 04:30 PM
Waisbourd RamSee RemarksNov 16Option Exercise1.937,00013,5107,000Nov 18 06:37 PM
Waisbourd RamSee RemarksNov 16Sale16.497,000115,4300Nov 18 06:37 PM
Waisbourd RamSee RemarksOct 18Option Exercise1.937,00013,5107,000Oct 20 04:30 PM
Waisbourd RamSee RemarksOct 18Sale17.497,000122,4300Oct 20 04:30 PM
Waisbourd RamSee RemarksSep 16Option Exercise1.937,00013,5107,000Sep 20 04:32 PM
Waisbourd RamSee RemarksSep 16Sale19.467,000136,2200Sep 20 04:32 PM
Waisbourd RamSee RemarksAug 16Option Exercise1.937,00013,5107,000Aug 18 04:10 PM
Waisbourd RamSee RemarksAug 16Sale18.287,000127,9600Aug 18 04:10 PM
Waisbourd RamSee RemarksJul 16Option Exercise1.937,00013,5107,000Jul 19 04:05 PM
Waisbourd RamSee RemarksJul 16Sale16.807,000117,6000Jul 19 04:05 PM
PALEKAR ROHANChief Executive OfficerJul 08Buy16.252,00032,50037,000Jul 08 04:05 PM
PALEKAR ROHANChief Executive OfficerJul 07Buy17.075,00085,35035,000Jul 08 04:05 PM
Waisbourd RamSee RemarksJun 16Option Exercise1.937,00013,5107,000Jun 21 04:30 PM
Waisbourd RamSee RemarksJun 16Sale19.677,000137,6900Jun 21 04:30 PM
RA CAPITAL MANAGEMENT, L.P.DirectorJun 02Buy18.7722,138415,5304,965,769Jun 04 04:31 PM
RA CAPITAL MANAGEMENT, L.P.DirectorMay 28Buy18.77123,5052,318,1894,943,631May 28 06:41 PM
RA CAPITAL MANAGEMENT, L.P.DirectorMay 27Buy18.7635,535666,6374,820,126May 28 06:41 PM
RA CAPITAL MANAGEMENT, L.P.DirectorMay 26Buy18.0348,377872,2374,784,591May 28 06:41 PM